ReviewNPJ schizophrenia2018
Studying and modulating schizophrenia-associated dysfunctions of oligodendrocytes with patient-specific cell systems.
Review in NPJ schizophrenia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Polygenic burden associated to oligodendrocyte precursor cells and radial glia influences the hippocampal volume changes induced by aerobic exercise in schizophrenia patients.Translational psychiatry · 2019Trial
- Model Systems infrastructure of the German Center for Mental Health (DZPG): toward an integrated, mechanism-based framework for mental health research.European archives of psychiatry and clinical neuroscience · 2026Review
- Bridging the Scales via Personalized Cellular Modeling and Deep Phenotyping in Schizophrenia.JAMA psychiatry · 2026Article
- Schizophrenia endophenotypes: a review of neurophysiological, neuropsychological, and social cognition markers.Frontiers in psychiatry · 2026Review
- Repurposing medications to prevent psychosis.Npj mental health research · 2025Review
- Oligodendrocytes and myelination: pioneering new frontiers in cognitive neuroscience.Frontiers in neuroscience · 2025Review
- Dysregulation of myelination-related genes in schizophrenia.Journal of neurochemistry · 2024Review
- Integrative cross-omics and cross-context analysis elucidates molecular links underlying genetic effects on complex traits.Nature communications · 2024Article
- Disturbed Oligodendroglial Maturation Causes Cognitive Dysfunction in Schizophrenia: A New Hypothesis.Schizophrenia bulletin · 2023Article
- Cracking the Code of Neuronal Cell Fate.Cells · 2023Review
- Transcriptional and bioinformatic analysis of GABAFrontiers in molecular neuroscience · 2023Article
- The multimodal Munich Clinical Deep Phenotyping study to bridge the translational gap in severe mental illness treatment research.Frontiers in psychiatry · 2023Article
- Activation of AExperimental and therapeutic medicine · 2022Article
- Comprehensive and integrative analyses identify TYW5 as a schizophrenia risk gene.BMC medicine · 2022Article
- Accurate identification of circRNA landscape and complexity reveals their pivotal roles in human oligodendroglia differentiation.Genome biology · 2022Article
- Article
- Comparative Neurodevelopment Effects of Bisphenol A and Bisphenol F on Rat Fetal Neural Stem Cell Models.Cells · 2021Article
- Genetic and environmental factors of schizophrenia and autism spectrum disorder: insights from twin studies.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Structural and Functional Features of Developing Brain Capillaries, and Their Alteration in Schizophrenia.Frontiers in cellular neuroscience · 2020Review
- Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia.Journal of immunology research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmortem studies in patients with schizophrenia (SCZ) have revealed deficits in myelination, abnormalities in myelin gene expression and altered numbers of oligodendrocytes in the brain. However, gaining mechanistic insight into oligodendrocyte (OL) dysfunction and its contribution to SCZ has been challenging because of technical hurdles. The advent of individual patient-derived human-induced pluripotent stem cells (hiPSCs), combined with the generation of in principle any neuronal and glial cell type, including OLs and oligodendrocyte precursor cells (OPCs), holds great potential for understanding the molecular basis of the aetiopathogenesis of genetically complex psychiatric diseases such as SCZ and could pave the way towards personalized medicine. The development of neuronal and glial co-culture systems now appears to enable the in vitro study of SCZ-relevant neurobiological endophenotypes, including OL dysfunction and myelination, with unprecedented construct validity. Nonetheless, the meaningful stratification of patients before the subsequent functional analyses of patient-derived cell systems still represents an important bottleneck. Here, to improve the predictive power of ex vivo disease modelling we propose using hiPSC technology to focus on representatives of patient subgroups stratified for genomic and/or phenomic features and neurobiological cell systems. Therefore, this review will outline the evidence for the involvement of OPCs/OLs in SCZ in the context of their proposed functions, including myelination and axon support, the implications for hiPSC-based cellular disease modelling and potential strategies for patient selection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.